Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07224971 · ClinicalTrials.gov registry record · Phase 2
Impact of Circadian Rhythm on Immunotherapy
A Phase 2 study of Advanced/Metastatic NSCLC, sponsored by Liza Villaruz, MD.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 350
- Enrollment target
- 1
- Study location
NCT07224971: Recruiting Phase 2 study of Advanced/Metastatic NSCLC, sponsored by Liza Villaruz, MD.
NCT07224971 is a Phase 2 study of Advanced/Metastatic NSCLC that is actively recruiting participants, run by Liza Villaruz, MD. The registered enrollment target is 350 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (163% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07224971, a Phase 2 study of Advanced/Metastatic NSCLC, is actively recruiting participants, sponsored by Liza Villaruz, MD.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 350 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to determine whether morning versus afternoon treatment impacts efficacy of (standard of care) immunotherapy in a broad patient population. Patients with any type of advanced/metastatic malignancy are eligible to enroll in this study, as long as first-line anti-PD-1/PD-L1 immunotherapy is on label for their condition. Participants will then be randomized to either the early treatment group (administration must start and conclude by 11:00 AM +1 hour window) or the late treatment group (administration must start after 12:00 PM).
Primary Outcome
Time from first dose of 1st line treatment to clinician documented clinical disease progression, initiation of new line of therapy, or death from any cause, whichever comes first. Real-world progression-free survival (rwPFS), defined as the time from first dose of 1st line treatment to clinician documented clinical disease progression, initiation of new line of therapy, or death from any cause, whichever came first. Per RECISIT v1.1, Progressive Disease: ≥20% increase in the sum of diameters of
Conditions Studied
Interventions
- DRUG Immunotherapy - PD-1 Blocker
Study Locations (1)
Pennsylvania
- UPMC Hillman Cancer Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2025-12-02 |
| Est. Completion | 2030-05-01 |
| Phase | Phase 2 |
What NCT07224971 shows while recruiting
NCT07224971 is an interventional study that assigns participants to a tested intervention. The registered 350 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (163% higher).
The record links to 1 condition, with Advanced/Metastatic NSCLC appearing as the primary indexed condition, and to 1 intervention - of which Immunotherapy - PD-1 Blocker is the first listed.
NCT07224971 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT07224971 about?
NCT07224971 is a clinical study titled "Impact of Circadian Rhythm on Immunotherapy". This study aims to determine whether morning versus afternoon treatment impacts efficacy of (standard of care) immunotherapy in a broad patient population. Patients with any type of advanced/metastatic malignancy are eligible to enroll in this study, as long as first-line anti-PD-1/PD-L1 immunothera...
What is the current status of trial NCT07224971?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 350 participants. The study started on 2025-12-02. Estimated completion is 2030-05-01.
What conditions does trial NCT07224971 study?
This clinical trial studies the following conditions: Advanced/Metastatic NSCLC.
What interventions are being tested in trial NCT07224971?
The interventions under investigation include: Immunotherapy - PD-1 Blocker (DRUG).
Who is sponsoring clinical trial NCT07224971?
This trial is sponsored by Liza Villaruz, MD, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07224971 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced/Metastatic NSCLC
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07224971's enrollment target sits among peer trials
350 130th of 2000 higher than 1,866 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00900575 · 350 participants · NA
Cervical Cancer Detection Using Optical Spectroscopy
- NCT01627821 · 350 participants · NA
Evaluation of the Jarvik 2000 Left Ventricular Assist System With Post-Auricular Connector--Destination Therapy Study
- NCT02357654 · 350 participants · Phase 4
GnRH for Luteal Support in IVF/ICSI/FET Cycles
- NCT03997370 · 350 participants · Phase 1
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI